1	Title: Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac®, Sinovac)							
2	And ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) Vaccinations in Thai Health Care							
3	Workers							
4	Watsamon Jantarabenjakul, MD, PhD ^{1,2,3} , Napaporn Chantasrisawad, MD ^{1,2,3} , Thanyawee Puthanakit,							
5	MD ^{2,3} , Supaporn Wacharapluesadee, PhD ⁴ , Nattiya Hirankarn MD, PhD ⁵ , Vichaya Ruenjaiman, PhD ⁵ ,							
6	Leilani Paitoonpong, MD ^{1,6} , Gompol Suwanpimolkul, MD ^{1,6} , Pattama Torvorapanit, MD ¹ , Rakchanok							
7	Pradit, MSN ¹ , Jiratchaya Sophonphan ⁷ , and Opass Putcharoen, MD ^{1,6}							
8	1. Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial							
9	Hospital, Bangkok, Thailand							
10	2. Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand							
11	3. Center of Excellence in Pediatric Infectious Diseases and Vaccines, Faculty of Medicine,							
12	Chulalongkorn University, Bangkok, Thailand							
13	4. King Chulalongkorn Memorial Hospital, Bangkok, Thailand							
14	5. Center of Excellence in Immunology and Immune-Mediated Diseases, Department of							
15	Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand							
16	6. Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand							
17	7. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross							
18	AIDS Research Centre, Bangkok, Thailand							
19	Short Running Title: Immune response after COVID-19 vaccination							
20	Corresponding author: Opass Putcharoen, MD							
21	Postal Address: Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn							
22	Memorial Hospital, Bangkok, Thailand, 10330							

- 23 Email: <u>Opass.p@chula.ac.th</u>, Work telephone: 02-256-4930
- 24 Clinical trial registration number: TCTR20210325003
- 25 250 for Abstract, 3362 for Text, 21 references, 3 tables, 3 figures and 4 supplementary tables

26	Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac®, Sinovac) And						
27	ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) Vaccinations in Thai Health Care						
28	Workers						
29	Abstract						
30	Background: Inactivated SARS-CoV-2 (CoronaVac®,Sinovac, or SV) and ChAdOx1 nCoV-19						
31	(Vaxzevria®,Oxford-Astra Zeneca, or AZ) vaccines have been administered to the health care workers						
32	(HCWs) in Thailand.						
33	Objective: To determine the short-term immune response after the SV and AZ vaccinations in HCWs.						
34	Methods: In this prospective cohort study, HCWs who completed a 2-dose regimen of the SV or AZ						
35	were included. Immune response was evaluated by surrogate viral neutralization test (sVNT) and anti-						
36	SARS-CoV-2 total antibody. Blood samples were analyzed at 4 and 12 weeks after the complete SV						
37	vaccination and at 4 weeks after each dose of the AZ vaccination. The primary outcome was the						
38	seroconversion rate at 4-weeks after complete immunization.						
39	Results: Overall, 185 HCWs with a median (IQR) age of 40.5(30.3-55.8) years (94 HCWs in the SV						
40	group and 91 in the AZ group) were included. At 4 weeks after completing the SV vaccination, 60.6%						
41	(95%CI:50.0-70.6%) had seroconversion evaluated by sVNT(≥68%inhibition), comparable to the						
42	patients recovered from mild COVID-19 infection(69.0%), with a rapid reduction to						
43	12.2%(95%CI:6.3-20.8) at 12 weeks. In contrast, 85.7%(95%CI:76.8-92.2%) HCWs who completed						
44	the second dose of the AZ for 4 weeks had seroconversion, comparable to the COVID-19 pneumonia						
45	patients(92.5%). When using the anti-SAR-CoV-2 total antibody level(≥132 U/ml) criteria, only						
46	71.3% HCWs in the SV group had seroconversion, compared to 100% in the AZ group.						

47	Conclusion: A rapid decline of short-term immune response in the HCWs after the SV vaccination						
48	indicates the need for a vaccine booster, particularly during the ongoing spreading of the SAR-CoV-2						
49	variants of concern.						
50	Keywords: SARS-CoV-2 vaccine, COVID-19 vaccine, Surrogate viral neutralizing antibody titer,						

51 Anti-SARS-CoV-2 total antibody, Health care workers, Inactivated SARS-CoV-2 vaccine

52 Introduction

53

54	syndrome coronavirus 2 (SARS-CoV-2) infection or Coronavirus diseases 2019 (COVID-19), several
55	SARS-CoV-2 vaccines have been developed and widely distributed. In Thailand, inactivated SARS-
56	CoV-2 (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca, or
57	AZ) vaccines have been administered to the front-line health care workers (HCWs) since March 2021.
58	While the SV is an inactivated whole-virion SARS-CoV-2 vaccine, the AZ is a replication-deficient
59	adenoviral vector vaccine. ^{1,2} Therefore, the immunological mechanisms of vaccine-induced protection
60	against SARS-CoV-2 in humans were different. ³

In general, natural infection creates a protective immunity against re-infection. However, in the 61 62 COVID-19 patients, the re-infection is possible, whereas the definitive antibody level for protective immunity remains inconclusive.^{4,5} Moreover, recent evidence suggests that a high neutralizing titer 63 may be required for protection against the circulating SAR-CoV-2 variants of concern (VOCs) 64 infection and symptomatic disease.^{6,7} To measure the SARS-CoV-2 vaccine-induced protective 65 immune response against the symptomatic infection, the neutralizing antibody titer against the SARS-66 CoV-2 is a highly predictive indicator. The gold standard for neutralizing antibody detection is a 67 plaque reduction neutralizing test (PRNT₅₀), which requires live pathogen and complex laboratory 68 settings. Therefore, the more simplified technique using surrogate virus neutralization test (sVNT), 69 70 which detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain (RBD), is generally used as a high sensitivity and specificity rapid test.⁸ 71 Additionally, the binding antibody (total antibodies including IgG, IgM, and IgA) against the SARS-72 73 CoV-2 can be detected with simple laboratory techniques, including rapid test, Enzyme-Linked 74 Immunosorbent Assay (ELISA), and Electrochemiluminescence Assay.

Our study, therefore, aimed to determine the immune response after the SV and AZ vaccination in the HCWs, in comparison with the patients recovered from the COVID-19 using sVNT (%inhibition) and anti-SARS-CoV-2 total antibodies (U/ml). Moreover, the correlation between the sVNT and anti-SARS-CoV-2 total antibodies for estimating vaccine efficacy against SARS-CoV-2 was evaluated.

80

81 Methods (935 words)

The prospective cohort study included HCWs who received the SARS-CoV2 vaccination at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. The study was approved by the Research Ethics Review Committee, Faculty of Medicine, Chulalongkorn University, and was registered to the Thai Clinical Trial (TCTR20210325003). The protocol was performed in accordance with the declaration of Helsinki and its later amendments. All participants were voluntary to receiving the

87 SARS-CoV-2 vaccination and participating in the study with written informed consent.

88 Study Population

Inclusion criteria were as follows: (1) HCWs aged 18 years old and above; and (2) no history 89 90 of the COVID-19. Patients who had (1) ongoing immunosuppressive medications; (2) any vaccinations within 1 month; or (3) any blood components or intravenous immunoglobulin 91 92 administrations within 3 months; were excluded. Overall, each vaccination group consisted of 50 participants aged 18-40 years and 50 aged 41-70 years. In the SV group, 0.5 ml (3 µg) of inactivated 93 94 SARS-CoV-2 (CoronaVac®, Sinovac, or SV) vaccine was administered intramuscularly at the deltoid region, using a 2-dose regimen with an interval of 21-28 days. For the ChAdOx1 nCoV-19 95 (Vaxzevria®, Oxford-AstraZeneca, or AZ) vaccination group, 0.5 ml of the AZ containing 5x10¹⁰ 96

viral particles was administered intramuscularly at the deltoid region, using a 2-dose regimen with an
interval of 8-10 weeks.

99	For the COVID-19 group, data were collected from patients diagnosed with the SARS-CoV-2
100	infection at the Emerging Infectious Diseases Clinical Center at King Chulalongkorn Memorial
101	hospital from March to April 2020, which, at that time, the wild-type SARS-CoV-2 was the main
102	circulating strain in Thailand. The COVID-19 was diagnosed by reverse transcriptase-polymerase
103	chain reaction (RT-PCR) of SARS-CoV-2 from the throat and nasopharyngeal swab samples. The
104	COVID-19 patients were classified according to the clinical severity into mild COVID-19 and
105	COVID-19 pneumonia.

106 Demographics and Clinical Data

Baseline demographics and clinical data, including medical history, current medications used,
 and a history of exposure to the COVID-19 patients, were collected. In addition, for the COVID-19
 patients, the clinical characteristics of the SARS-CoV-2 infections were evaluated.

110 Sample Collections and Study Protocol

111 For the vaccination groups, 4-ml clotted blood was collected at baseline for all participants,

- then at 4 and 12 weeks (+/-2 weeks) after the second dose of the SV vaccination and at 4 weeks (+/-2
- 113 weeks) after the first and second doses of the AZ vaccination.
- 114 For the COVID-19 group, the blood samples were collected at the time of diagnosis and 4±2
 115 weeks after diagnosis.

116 The Detection of Antibody Titers Against SARS-CoV-2

117 The antibody titers against SARS-CoV-2 were determined by the surrogate neutralizing118 antibody and total antibodies using the ELISA technique.

119 1. The SARS-CoV-2 Neutralizing Antibody

The SARS-CoV-2 neutralizing antibody was detected by the blocking ELISA technique of the 120 cPass[™] SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript), which the US Food and 121 Drug Administration (FDA) issued Emergency Use Authorizations (EUAs). The protein-protein 122 interaction between Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD 123 fragment (HRP-RBD), and the human ACE2 receptor protein (hACE2) can be blocked by neutralizing 124 125 antibodies against SARS-CoV-2 RBD. The neutralizing antibody level was detected as percent signal inhibition (%inhibition) following the manufacturer's protocol. Briefly, serum (negative or positive 126 127 controls) was diluted 10-fold in a sample diluent (as described in the package insert), mixed with HRP-RBD, then incubated at 37°C for 30 minutes. After incubation, the mixture was added to the 128 hACE2-coated well and incubated at 37°C for 30 minutes. The ELISA plate was then washed with a 129 130 wash solution for 4 times. The 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added and incubated for 15 minutes. Finally, the stop solution was added before the optical density (OD) value at 131 132 450 nm was read. The antibody level is described as the percentage of signal inhibition or %inhibition.⁸ The percent signal inhibition was calculated using the equation from the manufacturer 133 with the cut-off level for SARS-CoV-2 neutralizing antibody detection of \geq 30% inhibition. 134

135 Percent signal inhibition =
$$\left(1 - \frac{\text{OD value of sample}}{\text{OD value of negative control}}\right) \times 100\%$$

The seroconversion rate was defined as sVNT ≥68%, adopted from the USA-FDA guidance of
a high titer of the COVID-19 convalescent plasma.⁹

138 2. The SARS-CoV-2 Total Antibodies

139	The SARS-CoV-2 total antibodies were detected by the Elecsys® Anti-SARS-CoV-2 S using
140	Cobas e411 immunoassay analyzers (Roche Diagnostics, Rotkreuz, Switzerland), which is also the
141	US-FDA EUAs. The Elecsys® is the immunoassay for SARS-CoV-2 total antibodies against the RBD
142	of the S antigen detection, and the antibody level is reported as U/ml. Two hundred microliter of
143	serum sample was used following the manufacturer's protocol. The criteria of negative for anti-SARS-
144	CoV-2-S is <0.8 U/ml. For the participants who had the SARS-CoV-2 total antibodies over the
145	maximum measuring range (which is >250 U/ml), 10-fold diluted samples using the Elecsys® Diluent
146	Universal were re-evaluated. Moreover, the baseline serum of each participant in the vaccination
147	groups was confirmed to be negative for the SARS-CoV-2 total antibodies. ¹⁰ The seroconversion rate
148	was defined as the anti-SARS-CoV-2 total antibodies \geq 132 U/ml as suggested by the US-FDA of the
149	high titer for COVID-19 convalescent plasma. ⁹
150	The level of anti-SARS-CoV-2 total antibodies (measured in U/ml) from the Elecsys® test was
151	converted to the BAU/ml following the first WHO International Standard for anti-SARS-CoV-2
152	immunoglobulin, which 1 U/ml is equivalent to 0.972 BAU/ml. ¹¹
153	Statistical Analysis
154	Demographics and clinical and laboratory parameters were described in descriptive statistics.

Continuous variables were presented as median and interquartile range (IQR). The Wilcoxon rank-sum test was applied to compare the continuous variables between two groups and the Kruskal-Wallis test in case of more than two groups. The Chi-square test or Fisher exact test were used to compare the proportion between groups. The correlation between sVNT and anti-SARS-CoV-2 total antibodies was determined by the Spearman rank test. Statistical significance was considered as P<0.05. STATA version 15.1 (Stata Corp., College Station, Texas) was used for statistical analysis.

161 **Results**

For the vaccination groups, a total of 200 HCWs participated in the study. However, only 185 162 163 participants completed the 2-dose regimen of the vaccinations and had the blood collection at 1 month 164 after the second dose (94 and 91 participants in the SV and the AZ groups, respectively). The median 165 (IQR) intervals between the second dose and the blood collection were 23 (22-24) days for the SV 166 group and 19 (16-21) days for the AZ group. For the COVID-19 group, a total of 182 COVID-19 patients were admitted to King Chulalongkorn Memorial Hospital during March and April 2020. One 167 168 hundred eleven patients had convalescent sera collected at approximately 1 month after diagnosis with a median (IQR) interval of 35 (30-38) days. Of 111 patients, 58 were diagnosed with mild COVID-19 169 (including upper respiratory tract infection (URI)) and 53 with COVID-19 pneumonia (including 26 170 moderate and 23 severe pneumonia (who required oxygen supplement or ventilator support) patients). 171 172 Demographic data and clinical characteristics are described in Table 1. At baseline, the immune 173 response of all participants in the vaccination groups was confirmed to be negative by both tests.

174 The SARS-CoV-2 Neutralizing Antibodies (sVNT, %inhibition)

The sVNTs (%inhibition) at 4 weeks after completing the second dose of the vaccinations are
demonstrated in Table 2 and Figure 1. The median (IQR) of SARS-CoV-2 sVNT was 77.0 (58.5-87.9)
%inhibition in the SV group, 90.4 (75.2-96.2) %inhibition in the AZ group, 80.8 (61.5-92.1)
%inhibition in the mild COVID-19 group, and 94.5 (88.1-95.8) %inhibition in the COVID-19
pneumonia group.

For the SV group, sVNT tended to be lower in the older age group but was not statistically
 significant (83.2%inhibition in the 20-30 years group vs 73.4%inhibition in the 51-60 years group,
 P=0.18). There was no statistically significant difference of sVNT between age ranges and sexes in

each group. (Table 2) Comparing to the convalescent sera of the COVID-19 patients, the SV group
had a level of SARS-CoV-2 neutralizing antibodies comparable to the mild COVID-19 group. In
contrast, the AZ group had a higher level of neutralizing antibodies comparable to the COVID-19
pneumonia group. (Figure1)

At 12 weeks after the second dose of the SV vaccination, the median (IQR) of SARS-CoV-2 sVNT was 38.7 (22.1-55.7) %inhibition, which significantly decreased from the immune response at 4 weeks (77.0 (58.5-87.9) %inhibition) (P<0.001). (Figure 2A, Supplementary Table 1) On the contrary, the median (IQR) of SARS-CoV-2 sVNT at 4 weeks after the first dose of AZ was 37.6 (6.5-63.2) %inhibition and significantly increased after the second dose (P<0.001). (Figure 2B, Supplementary

192 Table 2)

193 For the US-FDA guidance of a high titer of the COVID-19 convalescent plasma, the %inhibition using the cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit should be 68% 194 and over (or $\geq 68\%$ inhibition). At 4 weeks after completing the vaccinations, 57/94 (60.6%) 195 196 participants in the SV group had $\geq 68\%$ inhibition, compared to 78/91 (85.7%) participants in the AZ group. (Table 3) However, only 11/90 (12.2%) participants in the SV group had the high titers at 12 197 198 weeks after the second dose. (Supplementary Table 1). For the AZ group, 18/87 (20.7%) participants had \geq 68% inhibition at 4 weeks after the first dose with the median (IQR) sVNT of 37.6 (6.5-63.2) 199 % inhibition. (Supplementary Table 2) 200

- For sensitivity analysis, a higher cPassTM SARS-CoV-2 Neutralization Antibody Detection
- Assays of \geq 80% inhibition was used as a surrogate marker for high sVNT against the SARS-CoV-2
- variants of concerns. Consequently, only 43/94 (45.7%) participants in the SV group and 64/91
- 204 (70.3%) participants in the AZ group had \geq 80% inhibition, compared to 46/53 (86.8%) patients in the
- 205 COVID-19 pneumonia group (P<0.001). (Table3)

206 The SARS-CoV-2 Total Antibodies

207	The median (IQR) of anti-SARS-CoV-2 total antibodies were 188.6 (115.6-312.2) U/ml in the								
208	SV group, 794.2 (497.9-1383.0) U/ml in the AZ group, 66.9 (19.7-170.2) U/ml in the mild COVID-19								
209	group, and 794.2 (497.9-1383) U/ ml in the COVID-19 pneumonia group. In the SV group, the anti-								
210	SARS-CoV-2 total antibodies among the older age group tended to be decreased but were not								
211	statistically significant (275.8 U/ml in the 20-30 years group vs 185.6 U/ml in the 51-60 years group,								
212	P=0.28).								
213	Using the US-FDA guidance of a high titer of the COVID-19 convalescent plasma, the cut-off								
214	index (COI) for the Elecys TM test anti-SARS-CoV-2 total antibodies is \geq 132 U/ ml. Using the US-								
215	FDA COI criteria, 67/94 (71.3%) participants in the SV group and 91/91(100%) participants in the AZ								
216	group had seroconversion. (Table 3) Notably, the anti-SARS-CoV-2 total antibodies of the AZ group								
217	were significantly higher than the COVID-19 pneumonia group (P<0.001). (Figure1)								
218	According to the generalized additive models to estimate the immune marker values, in this								
219	case, the anti-SARS-CoV-2 total antibodies using the Elecys TM kit technique (converted to BAU/ml),								
220	the vaccine efficacy of SV and AZ were 50% and 70%, respectively. ¹¹ (Supplementary Table 3, 4)								
221	Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total								
221 222	Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total Antibodies								
221 222 223	Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total Antibodies The Spearman correlation coefficient between the sVNT and the anti-SARS-CoV-2 total								
221 222 223 224	Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total Antibodies The Spearman correlation coefficient between the sVNT and the anti-SARS-CoV-2 total antibodies was 0.79 for the SV group and 0.86 for the AZ group. (Figure 3) Interestingly, 78/91								
 221 222 223 224 225 	Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total Antibodies The Spearman correlation coefficient between the sVNT and the anti-SARS-CoV-2 total antibodies was 0.79 for the SV group and 0.86 for the AZ group. (Figure 3) Interestingly, 78/91 (86.7%) participants in the AZ group had both high neutralizing antibodies (sVNT ≥68%inhibition)								
 221 222 223 224 225 226 	Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total Antibodies The Spearman correlation coefficient between the sVNT and the anti-SARS-CoV-2 total antibodies was 0.79 for the SV group and 0.86 for the AZ group. (Figure 3) Interestingly, 78/91 (86.7%) participants in the AZ group had both high neutralizing antibodies (sVNT ≥68%inhibition) and high binding antibodies (anti-SARS-CoV-2 total antibodies ≥132 U/ml), compared to 55/94								

228 Discussion

This study presented the short-term immune response of Thai HCWs after completing the 2dose regimens of both the SV and AZ for one month and at three months after the SV vaccination. In this study, the surrogate immune markers were used to predict the vaccine efficacy to protect against the SARS-CoV-2 infection and/or symptomatic disease.

The immune response of the AZ group as measured by the sVNT was higher than the SV 233 group (85.7% vs 60.8% inhibition). Additionally, the binding antibodies, or the anti-SARS-CoV-2 total 234 antibodies, of >132 IU/ml was 100% in the AZ group and only 71% in the SV group. At 3-month after 235 236 completing the SV vaccination, sVNT significantly declined to 12.2%. Similarly, the rapid decline of protective immunity was observed after the SARS-CoV-2 infection, as described by the progressive 237 238 decline of the sVNT after 5-8 weeks post-infection and the decreased systemic IgA antibody level at 8 weeks post-infection.¹²⁻¹³ In our study, HCWs who completed the 2-dose regimen of the SV 239 240 vaccination, demonstrated a rapid decrease of sVNT at 12 weeks afterwards, and the anti-SARS-CoV-241 2 total antibodies were just equivalent to the mild COVID-19 patients. As the SARS-CoV-2 neutralizing antibodies level implicated the vaccine efficacy against the SARS-CoV-2 infection and 242 243 symptomatic disease, the rapid reduction of the sVNT should prompt the concerns of reduced vaccine efficacy at 1-6 months after the complete SV vaccination. Moreover, the protective immunity against 244 245 the SARS-CoV-2 VOC tends to require a high sVNT, though the definitive level is inconclusive. Thus, HCWS who previously received the SV vaccination should have a vaccine booster to accelerate 246 the sVNT level. In the AZ group, though the immune response was low after the first dose, then 247 248 dramatically increase after the second dose. Therefore, the interval period of the vaccination should be 249 shortened to accelerate the sVNT level to protect against the SARS-CoV-2 VOC earlier.

13

250	The study in Chile reported the vaccine effectiveness of the SV to be 65.9% for the prevention
251	of COVID-19. ¹⁴ In our study, the seroconversion rate was an immune marker that implicated the
252	protective immunity against the SARS-CoV-2 infection. Therefore, the 60.8% seroconversion rate in
253	the SV group should be equivalent to the reported vaccine effectiveness from Chile. Notably, the study
254	in Chile was conducted during Feb-April 2021, when the circulating strains were Alpha (B.117) and
255	Gamma (P1). Furthermore, in the SV group, the immune response tended to decrease with age,
256	corresponding with the data from the phase 1/2 clinical trials of the SV in healthy adults aged 60 years
257	and older. ¹⁵ This finding supports the Thai government initial policy of vaccine allocation, provide the
258	SV to younger age group (18-59 years) and the AZ to the elderly (≥ 60 years).
259	In the AZ group, a robust immune response was observed in all age groups, including the
260	elderly, corresponding with the phase 2/3 study of the ChAdOx1 nCoV-19 vaccine in young and old
261	adults. ¹⁶ In addition, vaccine efficacy of the AZ was similar to the study in Brazil, South Africa, and
262	the UK. ¹⁷ Of note, the level of the AZ-induced immune response was 4-time higher than the
263	convalescent sera after the wild-type SARS-CoV-2 infection. However, vaccine efficacy was expected
264	to be reduced for the SARS-CoV-2 VOC. In Thailand, B1.617.2 (Delta) variant has been the main
265	circulating SARS-CoV-2 VOC since July 2021. According to the study from the serum of the mRNA-
266	1273 (Spikevax®, Moderna) vaccinated patients, the neutralizing antibody titers against Delta was 2.9
267	times less susceptible to neutralization ¹⁸ ; therefore, a booster vaccine may also require after the
268	complete AZ vaccination. The Com-Cov study also supported the new vaccine regimen of
269	heterogenous prime-boost COVID-19 vaccination using AZ prime and boost with mRNA-BNT162b2
270	(Comirnaty®, Pfizer–BioNTech). ¹⁹
271	A single dose of AZ also demonstrated efficacy in reducing the disease severity. Regarding the

immunological mechanism of the AZ vaccine-induced protection against SARS-CoV-2, the low sVNT

level after the first dose of AZ may be explained by the sole measurement of humoral response mainly
from the B-cell activation. However, as a viral vector vaccine, the cellular responses (including the T
cells) were also activated but were under-estimated by the sVNTs. Thus, the AZ-induced Th1 and
CD8 T cell activity after the first dose of the AZ may contribute to the vaccine efficacy in ameliorating
the disease severity.^{3,20}

Moreover, a correlation coefficient between sVNT and anti-SARS-CoV-2 total antibodies were 278 higher in the AZ group (0.86) than the SV group (0.79). The lower correlation coefficient may be 279 280 explained by the different immunological mechanisms of the inactivated viral vaccine, including the SV, which induces a lower neutralising antibody level. Consequently, though some individuals had 281 high titers of the SARS-CoV-2 total antibodies, the sVNT was low, indicating that the majority of 282 283 anti-SARS-CoV-2 total antibodies were not neutralizing antibodies. Although other non-neutralizing antibodies might also contribute to the protective immunity,³ the neutralization level is highly 284 predictive of immune protection.²¹ Therefore, the anti-SARS-CoV-2 total antibodies following the SV 285 286 vaccination might not sufficiently represent the immune response against the SARS-CoV-2 infection, using the more accessible laboratory technique. 287

There were several strengths of this study. Firstly, as the HCWs were the first group who received the SARS-CoV-2 vaccinations in Thailand, our data will guide the policymakers of the Thai National Vaccine Roll-Out Program to outline the vaccine programs for the country. Secondly, the HCWs has an effective surveillance protocol to screen for the SAR-CoV-2 infection. Therefore, if no episode of SARS-CoV-2 infection was documented, the immune response should solely result from the vaccination.

This study has some limitations. Firstly, there were no definitive cut-off level of the sVNT and the SARS-CoV-2 total antibodies for protection against both wild-type SARS-CoV-2 virus and the 296 SARS-CoV-2 VOC. Therefore, a high sVNT ≥68% and 80% inhibition by the US-FDA were adopted to implicate the protective immunity. Moreover, previous studies reported the high correlation 297 between the sVNT and the PRNT₅₀⁸ and the equivalent sVNTs of the convalescent sera of the severe 298 COVID-19 patients- Secondly, both sVNT and the SARS-CoV-2 total antibodies only represented the 299 humoral immune response. Further studies on the cellular immune responses after the vaccination are 300 301 ongoing, comparing the T-cell activities by the ELISpot assay between the individuals who received 302 the AZ and the SV vaccinations. Theoretically, the AZ vaccine, a viral vector vaccine platform, should have a better cell-mediated immune response than the SV vaccine, an inactivated virus vaccine 303 304 platform.

In general, a highly effective vaccine with the lowest possible side effects should be offered to the front-line HCWs. From our data, the HCWs who completed 2 doses of the SV vaccination should be considered for a booster vaccine, and the HCWs who received the first dose of the AZ vaccination should shorten the interval for the second dose.

309 Conclusion

310 During the COVID-19 pandemic, the HCWs are at very high risk, as they are the front-line 311 team to deal with the patients. Therefore, all protective measures, including non-pharmacological (including personal protective equipment) and pharmacological (including a SARS-CoV-2 312 vaccination), should be highly regarded. Currently, high proportions of young HCWs in Thailand 313 completed the SV vaccinations. However, after completing the vaccination, the short-term immune 314 response appeared to be lower in the SV group than in the AZ group. Moreover, the HCWs in the SV 315 316 group experienced a rapid decline of the immune response as early as three months after the complete 317 vaccination. In this study, our results emphasized the urgent need for the booster vaccine for the

HCWs, particularly in the SV vaccination, in amidst the circulating SARS-CoV-2 VOC such as thedelta strain.

320 Conflicts of Interest

321 The authors declare that there is no conflict of interest regarding the publication of this article.

322 Acknowledgements

323 We would like to thank all health care workers at King Chulalongkorn Memorial Hospital (KCMH) as

well as the study team including Saithip khumpiwdum, Phattharasuda Yodbutdee and Thitima

maneepornpol. We also thank Susama Chokesuwattanaskul, of the Department of Ophthalmology,

326 Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, for help

- 327 with manuscript editing.
- Funding: The Rachadaphiseksomphot Fund (RA(PO)002/64) from the Faculty of Medicine,

329 Chulalongkorn University and the King Chulalongkorn Memorial Hospital Fund for research (HA-64-

330 3300-21-024). NH was supported by the Ratchadaphiseksomphot Matching Fund from the Faculty of

331 Medicine, Chulalongkorn University. VR was supported by the Postdoctoral Fellowship Scholarships,

332 Ratchadapisek Somphot Fund, Chulalongkorn University. Part of this work was supported by the

333 Biobank, Faculty of Medicine, Chulalongkorn University.

334 Author contributions

335 TP, SW, NH, LP GP, and OP contributed substantially to the conception and design of this study. WJ,

NC, RP and PT contributed substantially to the acquisition of the data. WJ, NP, SW, VR, NH, TP and

337 JS analyzed and interpreted the data. WJ, NP, and TP drafted the manuscript. LP, GS, TP, SW, NH

and OP contributed substantially to the manuscript revision. All the authors approved the final version

submitted for publication and take responsibility for the statements made in the published article.

340 **Reference**

341	1.	Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
342		immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report
343		of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467-78.
344	2.	Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of
345		an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-
346		blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181-92.
347	3.	Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced
348		protection against COVID-19 in humans. Nat Rev Immunol. 2021:1-10.
349	4.	Wang J, Kaperak C, Sato T, Sakuraba. COVID-19 reinfection: a rapid systematic review of
350		case reports and case series. J Investig Med. 2021;69:1253-5.
351	5.	Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody
352		Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med.
353		2021;384:533-40.
354	6.	Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine
355		against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187-9.
356	7.	Bernal JL, Andrew N, Gower C, Gallaher E, Simmons R, et al. Effectiveness of COvid-19
357		vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021; Jul 21 doi:
358		10.1056/NEJMoa2108891. [Epub ahead of print].
359	8.	Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
360		neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein
361		interaction. Nat Biotechnol. 2020;38:1073-8.

362	9.	De Santis GC, Mendrone A, Langhi D Jr, Covas DT, Fabron A Jr, Cortez AJP, et al. Suggested
363		guidelines for convalescent plasma therapy for the treatment of COVID-19. Hematol Transfus
364		Cell Ther. 2021;43:212-3.
365	10.	Elecsys Anti-SARS-CoV-2. [cited 2021 Jul 16]. Available from:
366		https://www.fda.gov/media/137605/download
367	11.	Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against
368		symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv 21258528 [Preprint]. 2021
369		[cited 2021 Jul 10]. Available from: https://doi.org/10.1101/2021.06.21.21258528
370	12.	Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of
371		neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat
372		Commun. 2021;12:844.
373	13.	Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. Neutralizing
374		antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for
375		survival. Nat Commun. 2021;12:2670.
376	14.	Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an
377		Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021; Jul 7. doi:
378		10.1056/NEJMoa2107715. [Epub ahead of print].
379	15.	Iversen PL, Bavari S. Inactivated COVID-19 vaccines to make a global impact. Lancet Infect
380		Dis. 2021;21:746-8.
381	16.	Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.
382		Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
383		regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3
384		trial. Lancet. 2021;396:1979-93.

385	17. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and
386	efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
387	analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet.
388	2021;397:99-111.
389	18. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and
390	Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N
391	Engl J Med. 2021; Jul 7. doi: 10.1056/NEJMc2107799. [Epub ahead of print].
392	19. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD, et al. Heterologous
393	prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397:2043-6.
394	20. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell
395	and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in
396	a phase 1/2 clinical trial. Nat Med. 2021;27:270-8.
397	21. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
398	antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
399	infection. Nat Med. 2021;27:1205-11.

	Inactivated	ChAdOx1	All COVID-19	COVID-19		P-value
	SARS-CoV2	nCoV-19	disease	mild COVID-19	COVID-19 pneumonia	_
	(SV)	(AZ)	(N=111)	(N=58)	(N=53)	
	(N=94)	(N=91)				
Age, year, median	40.8	40.4	36	31 (26-38)	43 (32.5-50.5)	0.001 ^a
(IQR)	(30.8-51.4)	(29.6-60.4)	(27-47)			
Age group, n (%)						<0.001 ^b
• 20-30 year	26 (27.7)	30 (33)	40 (36)	28 (48.3)	12 (22.6)	
• 31-50 year	44 (46.8)	19 (20.9)	54 (48.7)	27 (46.7))	27 (50.9)	
• 51-70 year	24 (25.5)	42 (46.2)	17 (15.3)	3 (5.2)	14 (26.4)	
Female, n (%)	76 (80.9)	68 (72.3)	67 (60.4)	37 (63.8)	30 (57.7)	0.005 ^b
BMI (kg/m ²),	22	22.8	22.5	20.8	23.4 (19.8-27.1)	0.45 ^a
median (IQR)	(20.1-25.6)	(20.3-25.6)	(19.5-26.7)*	(18.8-23.2)		

ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) or patients with COVID-19 diseases

Table 1: Demographics data of health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and

Interval between	23 (22-24)	19 (16-21)	35 (30-38)	34 (30-38)	35 (31-39)	NA
vaccine completion						
or COVID-19						
diagnosis and the						
blood collection, day,						
median (IQR)						
*N=55						

a indicates P-value from Kruskal-Wallis test and b from Chi-square test

Abbreviations: IQR=interquartile range

Table 2: Median (IQR) of the SARS-CoV2 Neutralizing antibody using the cPassTM test and the anti-SARS-CoV-2 total antibody using the ElecysTM test at 4 weeks after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to convalescent sera after COVID-19 disease

Median	SARS	SARS-CoV2 Neutralizing antibody (%inhibition)Anti-SARS-CoV-2 total antibody (U/mL)			Anti-SARS-CoV-2 total antibody (U/mL)					
(IQR)	Inactivated	ChAdOx1	mild	COVID-19	P-value ^a	Inactivated	ChAdOx1	mild	COVID-19	P-value ^a
	SARS-CoV2	nCoV-19	COVID-19	pneumonia		SARS-CoV2	nCoV-19	COVID-19	pneumonia	
	(SV)	(AZ)	(N=58)	(N=53)		(SV)	(AZ	(N=58)	(N=53)	
	(N=94)	(N=91)				(N=94)	(N=91)			
Overall	77.0	90.4	80.8	94.5	< 0.001	188.6	794.2	66.9	241.3	< 0.001
	(58.5-87.9)	(75.2-96.2)	(61.5-92.1)	(88.1-95.8)		(115.6-312.2)	(497.9-1383.0)	(19.7-170.2)	(170.3-442.9)	
Age, year										
20-30	83.2	88.2	74.7	91	0.03	275.8	583.1	49.2	183.1	< 0.001
	(59.0-92.7)	(78.1-95.9)	(52.9-89.9)	(76.2-94.5)		(101.1-580.2)	(459.7-864.7)	(14.9-119.9)	(81-244.2)	
31-50	77.3	95.6	89.5	94.7	< 0.001	187.6	933.6	125.9	241.3	< 0.001
	(59.1-87.5)	(75.6-97.9)	(64-94.3)	(89.8-95.7)		(115.6-282.3)	(516.2-1949)	(18.1-192.1)	(181.1-495.8)	
51-70	73.4	90.2	84.7	95.7	< 0.001	185.6	841.2	39.9	376.8	0.001

	(49.3-83.2)	(72.5-95.6)	(71.3-92.1)	(93.8-96.8)		(129.9-286.3)	(497.9-1657)	(21.9-226.1)	(207.9-936.4)	
P-value ^a	0.11	0.27	0.39	0.04		0.22	0.09	0.32	0.04	
Sex										
Male	67.9	85.4	71.3	95.3	< 0.001	180.1	735.4	40.8	411.1	< 0.001
	(58.5-86.2)	(74.0-93.8)	(53.5-89.4)	(91.8-96.1)		(101.1-227.1)	(447.6-886.4)	(5.42-108.7)	(241.3-866.9)	
Female	78.6	91.1	84.6	93.8	< 0.001	222.5	834.1	107.5	208.1	< 0.001
	(57.0-88.5)	(75.2-96.9)	(72.1-92.7)	(87.7-95.6)		(120.5-339.1)	(506.9-1506)	(21.8-192.1)	(142.7-354.6)	
P-value ^b	0.59	0.16	0.10	0.13		0.42	0.18	0.15	0.01	

a indicates P-value from Kruskal-Wallis test and b from Wilcoxon rank sum test

Table 3: The seroconversion rates of health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) and patients with COVID-19 infection who achieved the SARS-CoV2 neutralizing antibody \geq 68% inhibition and \geq 80% inhibition and anti-SARS-CoV-2 total antibody of \geq 132 U/mL

Seroconversion rate	Inactivated SARS-CoV2	ChAdOx1 nCoV-19	Mild COVID-19	COVID-19	P-value
	(SV)	(AZ)	(N=58)	Pneumonia	
	(N=94)	(N=91)		(N=53)	
%Inhibition ≥68% (N, (%))	57 (60.6)	78 (85.7)	40 (69)	49 (92.5)	< 0.001
%Inhibition ≥80% (N, (%))	43 (45.7)	64 (70.3)	30 (51.7)	46 (86.8)	< 0.001
SARS-CoV-2 total antibody	67 (71.3)	91 (100)	20 (34.5)	44 (83)	< 0.001
≥132 U/mL (N, (%))					

P-value from Chi-square test



Figure 1: A. the SARS-CoV-2 Neutralizing antibody using the cPassTM test (% inhibition) B. the anti-SARS-CoV-2 total antibody using the ElecysTM test (U/mL) after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to convalescent sera after COVID-19 diseases



Figure 2: A. The kinetic of the SARS-CoV-2 Neutralizing antibody using the cPassTM test (% inhibition) in health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) at 4 and 12 weeks after complete 2-dose immunization. B. in health care workers who received ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) at 4 weeks after the first and the second dose of immunization



Figure 3: Correlation between the SARS-CoV-2 neutralizing antibody using the cPassTM test (% inhibition) and the anti-SARS-CoV-2 total antibody using the ElecysTM test (U/mL) in health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) (A) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) (B) vaccination.

Supplement Table 1. The median (IQR) of the SARS-CoV-2 neutralizing antibody using the cPassTM test (% inhibition) in health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) at 4-week and 12-week after complete immunization.

	SARS-CoV-2 Neutralizing antibody using the cPass TM test (%inhibition)							
Median, (IQR)	Weeks 4	Weeks 12	P-value ^a					
	N=94	N=90						
Overall	77.0 (58.5-87.9)	38.7 (22.1-55.7)	<0.001					
Age, year								
20-30	83.2 (59.0-92.7)	40 (31.7-66)	< 0.001					
31-50	77.3 (59.1-87.5)	43.7 (21.2-57.4)	< 0.001					
51-70	73.4 (49.3-83.2)	32.4(15.3-43.3)	< 0.001					
P-value ^b	0.11	0.06						
Sex								
Male	67.9 (58.5-86.2)	37 (15.1-58.3)	0.006					
Female	78.6 (57.0-88.5)	38.8 (27.6-55.8)	< 0.001					
P-value ^c	0.59	0.85						

a indicates P-value from Wilcoxon sign rank test, b from Kruskal-Wallis test and c from Wilcoxon rank sum test

Supplement Table 2. The median (IQR) of the SARS-CoV-2 neutralizing antibody using the cPassTM test (% inhibition) in health care workers who received ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) at 4-week and 12-week after the 1st and 2nd dose immunization.

	SARS-CoV-2 Neutralizing antibody using the cPass TM test (%inhibition)							
Median, (IQR)	After 1 st dose immunization	After 2 nd dose immunization	P-value ^a					
	N=87	N=87						
Overall	37.6 (6.5-63.2)	90.4 (74.7-96)	< 0.001					
Age								
20-30 year	43.2 (29.9-72)	88.2 (76.6-95.8)	< 0.001					
31-50 year	56.1 (24.5-74.2)	95.8 (75.6-97.9)	< 0.001					
51-70 year	15 (0-44.4)	90.2 (72.5-95.3)	< 0.001					
P-value ^b	0.002	0.18						
Sex								
Male	35.5 (1.7-51.9)	85.4 (72.5-93.6)	< 0.001					
Female	38.6 (13-68.9)	91.1 (75.2-96.7)	< 0.001					
P-value ^c	0.38	0.13						

a indicates P-value from Wilcoxon sign rank test, b from Kruskal-Wallis test and c from Wilcoxon rank sum test

Supplementary Table 3: Median (IQR) of the anti-SARS-CoV-2 total antibody (BAU/mL) using the ElecysTM test at 4 weeks after complete 2dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to compare to convalescent sera after COVID-19 disease

Median	Anti-SARS-CoV-2 Total antibody titer (BAU/mL)						
(IQR)	Inactivated SARS-CoV2	ChAdOx1 nCoV-19	mild COVID-19	COVID-19 Pneumonia	P-value		
	(SV)	(AZ)	(N=58)	(N=53)			
	(N=94)	(N=91)					
Overall	194 (118.9-321.2)	817.1 (512.2-1422.8)	68.9 (20.2-175.1)	248.3 (175.2-454.6)	< 0.001		
Age, year							
20-30	283.7 (104-596.9)	599.8 (472.9-889.6)	50.6 (15.3-123.4)	188.4 (83.3-251.2)	< 0.001		
31-50	193 (118.9-290.4)	960.5 (531.1-2005.1)	129.5 (18.6-197.6)	248.3 (186.3-510.1)	< 0.001		
51-70	190.9 (133.6-294.5)	865.4 (512.2-1704.7)	41.1 (22.5-232.6)	387.7 (213.9-963.4)	< 0.001		
P-value	0.22	0.09	0.32	0.04			
Sex							
Male	185.2 (104-233.6)	756.5 (460.5-911.9)	41.9 (5.6-111.8)	422.9 (248.3-891.9)	< 0.001		

Female	228.9 (124-348.9)	858.1 (521.5-1549.4)	110.6 (22.4-197.6)	214.1 (146.8-364.8)	< 0.001		
P-value	0.42	0.18	0.15	0.01			
a indicates P-value from Kruskal-Wallis test and b from Wilcoxon rank sum test							

Remarks: The level of anti-SARS-CoV-2 total antibody (measured in U/mL) from the Elecsys® test was converted to the BAU/mL following

the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin, which 1 U/ml is equivalent to 0.972 BAU/ml.¹¹

Supplementary Table 4: Vaccine efficacy according to the generalized additive models with immune marker values, which is anti-SARS-CoV-2 total antibody (BAU/mL) using the ElecysTM kit technique⁹ in health care workers after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to compare to convalescent sera after COVID-19 disease

Vaccine Efficacy	Anti-SARS-CoV-2 total antibody (BAU/mL)							
	Inactivated SARS-CoV2	ChAdOx1 nCoV-19	mild COVID-19	COVID-19	P-value			
	(SV)	(AZ)	(N=58)	pneumonia				
	(N=94)	(N=91)		(N=53)				
50% (≥18 BAU/mL)	94 (100)	91 (100)	45 (77.6)	53 (100)	< 0.001			
60% (≥50 BAU/mL)	88 (93.6)	91 (100)	31 (53.5)	50 (94.3)	< 0.001			
70% (≥165 BAU/mL)	58 (61.7)	91 (100)	17 (29.3)	41 (77.4)	< 0.001			
80% (≥506 BAU/mL)	13 (13.8)	69 (75.8)	0	11 (20.8)	< 0.001			
90% (≥2360 BAU/mL)	0	7 (7.7)	0	0	0.001			











Spearman rank correlation=0.79; P < 0.001

64 128 256 512 1024 2048 Elecsys® Anti-SARS-CoV-2 (U/ml)

4096 8192

 100_{\neg} 90-80-70-% inhibition 60-50-30-

20 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 -

10-

B

